Contract to supply 5 million doses of anthrax vaccine valued at $120 million

GAITHERSBURG, Md. — Emergent BioSolutions Inc. announced May 5, 2006, that the Department of Health and Human Services has modified its contract and is purchasing an additional 5 million doses of BioThrax, the only FDA-licensed anthrax vaccine, for the nation’s Strategic National Stockpile.

BioThrax is manufactured by Emergent BioSolutions’ wholly owned subsidiary, BioPort Corp.

Emergent BioSolutions’ first contract to supply BioThrax was executed in 2005. The company completed deliveries of the initial 5 million doses in February 2006, eight months ahead of schedule. Fulfillment of this procurement will result in a total delivery of 10 million doses of BioThrax to the Strategic National Stockpile.

“We are proud to play a vital role in the strategic defense of the United States and the protection of its citizens in the event of another anthrax attack,” said Chairman and CEO Fuad El-Hibri.

“Moreover, we share the objective of the administration and key congressional leaders in securing a sufficient stockpile of safe and effective vaccines to protect the American public. We welcome the opportunity to continue to work closely with the Department of Health and Human Services to meet the strategic biodefense requirements of the government.”